返回 Agenda
Session 3: European Methodology at the Heart of the HTA Regulation - What is required to achieve the outcomes?
Session Chair(s)
Lara Wolfson
AVP & Head, HTA Statistics
MSD Switzerland, Switzerland
Roisin Adams
Deputy Head
National Centre for Pharmacoeconomics (NCPE), Ireland
The central question for this session is how can we adapt to meet the evolving space of new methodologies and technologies, and leverage modern tools and information visualization to support informed, patient and provider relevant assessments?
Speaker(s)
The Process
Anne Willemsen, MSc
ZIN - National Health Care Institute, Netherlands
Senior Project Manager, Joint Production Co-Lead Partner - Pharmaceuticals
Scene setting presentation: Case study in line with the importance of agreeing on joint methodologies for predictability
James Ryan, MSc
AstraZeneca (Global), UK, United Kingdom
Director, Global HTA Policy
National HTA Agencies Perspective
Beate Wieseler
IQWiG, Germany
Head of Department, Institute for Quality and Efficiency in Health Care
National HTA Agencies Perspective
Anja Schiel, PhD
Norwegian Medical Products Agency (NOMA), Norway
Special Advisor, Lead Methodologist/Statistician; NOMA
EMA Perspective
Steffen Thirstrup, MD, PhD
European Medicines Agency, Netherlands
Chief Medical Officer